MARLBOROUGH, Mass.,
May 20, 2019 /PRNewswire/
-- Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a
biotechnology company developing the next generation of
immuno-oncology therapeutics based on its proprietary
self-delivering RNAi (sd-rxRNA®) therapeutic platform,
will be presenting at the Sachs Associates 5th Annual
Immuno-Oncology BD&L and Investment Forum in Chicago.
Logo -
https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
Dr. Gerrit Dispersyn, Dr. Med. Sc., President and CEO, will
present an overview of the Company's RNAi technology, its relevance
in immuno-oncology and an update on the Company's product
development activities in this field. The presentation will be held
in Track B of the Faulkner Room of the Waldorf Astoria Chicago
Hotel at 11:50 AM CT on May 31, 2019.
The presentation will be available under the "Investors – Events
and Presentations" section of the Company's website,
www.phiopharma.com, approximately one hour following the
presentation.
The Company will also be attending the American Society of
Clinical Oncology (ASCO) Annual Meeting being held at McCormick
Place in Chicago from May 31 – June 4,
2019 and will be available for investor and company meetings
throughout the conferences.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a
biotechnology company developing the next generation of
immuno-oncology therapeutics based on its self-delivering RNAi
(sd-rxRNA®) therapeutic platform. The Company's efforts are focused
on developing sd-rxRNA therapeutic compounds to be used in the
context of immunotherapy by targeting checkpoints or other gene
targets, by local or intravenous injections. Our goal is to
maximize the power of our sd-rxRNA therapeutic compounds by
weaponizing immune effector cells to overcome tumor immune escape
providing patients with a powerful new treatment option that goes
beyond current treatment modalities. For additional information,
visit the Company's website, www.phiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are neither historical facts nor
assurances of future performance. These statements are based only
on our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results may
differ materially from those indicated in the forward-looking
statements as a result of a number of important factors, including,
but not limited to, the safety and efficacy of our product
candidates, future success of our clinical trials and scientific
studies, expected duration of available cash runway, our ability to
enter into strategic partnerships and the future success of these
strategic partnerships, the availability of funds and resources to
pursue our research and development projects and general economic
conditions. Our Annual Report on Form 10-K and subsequent
Quarterly Reports on Form 10-Q include detailed risks under the
caption "Risk Factors" that may affect our business, results of
operations and financial condition. Readers are urged to review
these risk factors and to not act in reliance on any
forward-looking statements, as actual results may differ from those
contemplated by our forward-looking statements. Phio does not
undertake to update forward-looking statements to reflect a change
in its views, events or circumstances that occur after the date of
this release.
Contact
Phio Pharmaceuticals Corp.
ir@phiopharma.com
View original
content:http://www.prnewswire.com/news-releases/phio-pharmaceuticals-to-present-at-sachs-associates-5th-annual-immuno-oncology-bdl-and-investment-forum-300852852.html
SOURCE Phio Pharmaceuticals Corp.